Stryker wins HDE approval for aneurysm-treating stent system

Some aneurysms require no treatment, while others are treated with drugs or surgery to prevent their rupture.

The FDA approved Stryker’s stent system that, along with neurovascular embolic coils, treats multiple types of aneurysm. The nod comes under a humanitarian device exemption (HDE).

The Neuroform Atlas device is a small nitinol stent used in conjunction with neurovascular embolic coils to treat wide neck, intracranial, saccular aneurysms. Aneurysms occur when part of an artery wall weakens and widens or balloons out.

"The hybrid cell stent design of Neuroform Atlas is designed to improve wall apposition, ease of use, deployment accuracy, and catheter re-entry in even the most challenging cases," said Osama Zaidat, M.D., a co-principal investigator and director of the Neuroscience and Stroke Center at Mercy Hospital in Toledo, Ohio. "The Atlas design may improve patient care by facilitating the treatment of wide neck aneurysms in tortuous and more complex anatomies."


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Aneurysms often present no symptoms and can develop over several years, according to the American Heart Association. But a ruptured aneurysm can cause various symptoms—including pain, shock and low blood pressure—and constitutes a medical emergency.

Some aneurysms do not require treatment, while others may be treated with drugs that reduce pressure on the blood vessel and lower the risk of the aneurysm rupturing. Others still may require stenting, but this is not an option for aneurysms in some parts of the body.

"Atlas opens up treatment options for a new segment of patients that would otherwise have been considered too risky to treat,” said Brian Jankowitz, M.D., a co-principal investigator of the investigational trial and director of the NeuroEndovascular Fellowship program at the University of Pittsburgh Medical Center.

The stent system was already available in a number of countries, and Stryker plans to roll the device out in the U.S. immediately.

Suggested Articles

The response rate was lower in the ONCOS-102 arm than the control cohort, but Targovax saw positives elsewhere.

The €13.9 million series B round will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.